# Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07772024/  
OnCo record `nct07772024` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Inobrodib run by CellCentric Ltd., now recruiting.

## Summary

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07772024 by CellCentric Ltd., with 450 participants planned, started 2026-08, primary completion expected 2029-11. Conditions recorded: Multiple Myeloma Refractory, Multiple Myeloma in Relapse. Interventions recorded: InoPd, Investigator's choice of SAT.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07772024
- Phase: 3
- Setting: A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate Inobrodib in Combination With Pomalidomide and Dexamethasone Versus Standard Available Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: CellCentric Ltd.
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07772024: https://clinicaltrials.gov/study/NCT07772024

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Inobrodib](https://onco.cc/drugs/inobrodib/)
- companies: [CellCentric](https://onco.cc/companies/cellcentric/)

---
JSON: https://onco.cc/api/v1/entities/nct07772024.json